Cornerstone Robotics raises additional capital to support global rollout of Sentire surgical platform
The announcement
Cornerstone Robotics, the Hong Kong-based developer of surgical robotic systems, has secured approximately $70 million in new funding to support its expansion into Europe and Southeast Asia. The financing round, completed in January 2025, follows a substantially larger $200 million raise in November 2024 that was earmarked for accelerating the global commercialization of the company’s Sentire surgical system.
The January 2025 round brings Cornerstone’s total fundraising for the year to roughly $270 million when combined with the November 2024 figure, though the company has not disclosed the specific investors participating in either round. The company has positioned the fresh capital as a means to deepen its presence in key international markets, with Europe and Southeast Asia named as priority geographies for growth.
Cornerstone’s stated mission is to make high-quality surgical care more accessible and efficient. The company has said its robotic platform is already in use at hospitals across mainland China and Hong Kong, providing a domestic base of clinical experience that it now aims to replicate abroad.
The funding announcement arrives at a moment of significant momentum for the company. In September 2024, Cornerstone received regulatory approval from China’s National Medical Products Administration (NMPA) for its Sentire robot. That approval cleared the way for domestic commercialization, and the company has since been working to establish a foothold in international markets.
The November 2024 round, described by the company as its second financing of that year, was specifically framed as a catalyst for speeding up the global commercialization of its surgical platform. In a statement accompanying that announcement, Cornerstone said it would “remain committed to innovation-driven development and deepen our global presence, bringing safe, high-quality, and accessible surgical robotic solutions to patients and healthcare providers around the world.”
The January 2025 round builds on that commitment, providing additional runway for the company’s international ambitions. While Cornerstone has not disclosed the exact allocation of the new funds, the company has indicated that Europe and Southeast Asia are the primary targets for expansion.
Product and availability details
The Sentire surgical system is designed to perform minimally invasive procedures across multiple surgical specialties. According to the company, the platform has received the European Union’s CE mark, which permits its use for minimally invasive procedures in general surgery, gynecology, thoracic surgery, and urology.
The CE mark certification represents a critical regulatory milestone for Cornerstone, as it opens the door to the European market, where the company will compete with established players and emerging challengers alike. The certification process was supported by a clinical partnership with Portsmouth Hospitals University NHS Trust in the United Kingdom, where Cornerstone conducted a trial last year to support adoption of the robot.
The company’s regulatory pathway has been methodical. The NMPA approval in September 2024 marked the first major regulatory clearance for the Sentire system. That was followed by the CE mark, which extends the platform’s reach into the European Economic Area. Cornerstone has not disclosed whether it has submitted the Sentire system for regulatory review in other jurisdictions, nor has it provided a timeline for potential approvals in Southeast Asian markets.
The Sentire system has been used in hospitals across mainland China and Hong Kong, according to the company. Clinical experience from these sites has informed the platform’s development and provided the basis for its international expansion.
One notable aspect of the Sentire system is its design familiarity for surgeons trained on other robotic platforms. In findings published in the Hong Kong Medical Journal, surgeons noted that the similarity of the robotic control interfaces—including hand controls and foot pedals—between Sentire and the da Vinci system allowed them to adopt the new platform more readily and apply their existing robotic experience. This design consideration could be a factor in the company’s ability to penetrate markets where surgeons already have significant experience with established robotic systems.
Cornerstone has not disclosed pricing for the Sentire system, nor has it provided details on service agreements, maintenance costs, or consumables pricing. The company has also not published specific performance metrics, such as procedure times, complication rates, or learning curves for surgeons new to the platform. These details remain undisclosed, and prospective buyers would need to engage directly with Cornerstone for such information.
The company has not announced specific availability dates for the Sentire system in European markets, nor has it identified which countries within the EU will be the first to receive the platform. Similarly, the company has not disclosed which Southeast Asian markets are being prioritized for expansion.
What it means for buyers
For hospitals and healthcare providers in Europe, the entry of Cornerstone into the market introduces another option in the rapidly growing field of surgical robotics. The company will be competing in soft tissue surgery against a field that includes Intuitive Surgical, the market leader with its da Vinci platform, as well as CMR Surgical, Distalmotion, Moon Surgical, and Medtronic.
The competitive landscape is significant. Intuitive Surgical has long dominated the market, and its da Vinci system is widely regarded as the benchmark for robotic-assisted surgery. However, the entry of multiple challengers in recent years has created a more diverse market with varying price points, form factors, and clinical focuses.
For buyers evaluating the Sentire system, the CE mark certification is a key indicator that the platform meets European regulatory standards for safety and performance. The clinical trial conducted with Portsmouth Hospitals University NHS Trust provides some evidence of the system’s usability in a European healthcare setting, though the company has not published detailed results from that trial.
The design similarity between Sentire and da Vinci control interfaces could be a practical advantage for hospitals with surgeons already trained on the da Vinci system. Reduced retraining time and a shorter learning curve could translate into faster adoption and potentially lower costs associated with surgeon training. However, Cornerstone has not published specific data on training requirements or learning curves, so buyers would need to assess these factors directly.
The company’s stated mission of making high-quality surgical care more accessible and efficient suggests a value proposition centered on cost-effectiveness and broad applicability. However, Cornerstone has not disclosed pricing information, and it remains unclear how the Sentire system will be positioned relative to competitors on cost.
For buyers in Southeast Asia, the company’s expansion plans could bring a new option for robotic-assisted surgery in a region where access to such technology has historically been limited. The company’s experience in mainland China and Hong Kong may provide relevant insights for healthcare systems in Southeast Asia, though the regulatory and operational environments differ across countries in the region.
The broader market context is favorable for surgical robotics. According to a report from The Robot Report’s sister publication MassDevice, the global surgical robotics market will double by 2029. The market is already worth billions of dollars, and the growth forecast reflects increasing adoption of robotic-assisted surgical technologies across multiple specialties.
For buyers, this growth means more choices and potentially more competitive pricing as new entrants like Cornerstone challenge the established players. However, it also means that buyers must navigate a more complex landscape of options, each with its own strengths, limitations, and support requirements.
Cornerstone has not disclosed details on service and support infrastructure in Europe or Southeast Asia. The company has not published information on response times, spare parts availability, or service level agreements. Buyers considering the Sentire system would need to obtain these details directly from the company.
The company has also not disclosed the total number of Sentire systems installed globally, nor has it provided procedure volume data. These metrics, which are commonly used to assess the maturity and reliability of surgical robotic platforms, remain undisclosed.
For healthcare providers evaluating the Sentire system, the available information suggests a platform with regulatory clearances in China and Europe, clinical use in hospitals across mainland China and Hong Kong, and a design that leverages familiarity with existing robotic interfaces. The company’s substantial fundraising—$270 million across two rounds in late 2024 and early 2025—indicates strong investor confidence in its commercial prospects.
However, the absence of published pricing, service details, and clinical outcomes data means that buyers will need to conduct their own due diligence. The company’s entry into the European market is recent, and its track record in the region is limited to the clinical trial conducted with Portsmouth Hospitals University NHS Trust.
The competitive pressure in the European market is intense. Intuitive Surgical’s established presence, combined with the recent entries of CMR Surgical, Distalmotion, Moon Surgical, and Medtronic, means that Cornerstone will need to differentiate itself on factors such as pricing, clinical outcomes, ease of adoption, or total cost of ownership. The company has not yet articulated a clear differentiation strategy beyond its mission of accessibility and efficiency.
For buyers, the arrival of Cornerstone adds another data point in a market that is evolving rapidly. The company’s CE mark certification provides a baseline of regulatory compliance, and its fundraising success suggests financial stability. However, the practical considerations of adopting the Sentire system—including training, service, and long-term support—remain to be clarified.
The company’s expansion into Southeast Asia is at an earlier stage, with no regulatory approvals or commercial partnerships disclosed for that region. Buyers in Southeast Asia would need to assess the company’s commitment to the region and its ability to provide local support.
In summary, the Sentire system offers a new option for buyers in Europe and, potentially, Southeast Asia. The platform has received regulatory clearances in two major markets, has been used in clinical settings in China and Hong Kong, and is backed by substantial funding. However, key details on pricing, service, and clinical performance remain undisclosed, and buyers will need to engage directly with Cornerstone to obtain the information necessary for a comprehensive evaluation.
The surgical robotics market is growing, and the entry of new players like Cornerstone is likely to increase competition and potentially drive innovation and cost reductions. For buyers, this is a positive development, but it also requires careful evaluation of each platform’s specific capabilities, costs, and support infrastructure.
Cornerstone’s progress to date—from NMPA approval in September 2024 to CE mark certification and a $70 million funding round in January 2025—demonstrates a company executing on its global expansion strategy. The company’s ability to secure substantial funding in a competitive investment environment suggests confidence in its technology and market position.
As the company moves forward, buyers will be watching for additional details on pricing, service infrastructure, and clinical outcomes. The company’s success in Europe and Southeast Asia will depend on its ability to provide compelling value to hospitals and healthcare systems in these regions, where competition is intense and buyers are increasingly sophisticated in their evaluation of surgical robotic platforms.
The Sentire system’s design, which allows surgeons with da Vinci experience to adopt the platform more readily, could be a significant advantage in markets where da Vinci is already established. However, the company will also need to demonstrate the system’s clinical effectiveness and reliability through published outcomes and long-term performance data.
For now, the available information provides a foundation for evaluating the Sentire system, but many details remain undisclosed. Buyers should expect to conduct thorough due diligence and seek direct engagement with Cornerstone to obtain the specific information needed for their procurement decisions.
Published by Vigla Media OÜ (Estonia).
Sources
- https://www.therobotreport.com/cornerstone-robotics-brings-70m-scale-sentire-endoscopic-system-globally/